1Dalton HJ.Outcome following pediatric ECMO[A].In:Zwischenberger JB,Steinhorn RH,Bartlett RH,editors.ECMO:extracorporeal cardiopulmonary support in critical care[M].2nd ed.Ann Arbor,Mich'ELSO,2000.481-493.
2Watson JW,Brown DN,Lally KP,et al.Complications of extracorporeal membrane oxygenation in neonates[J].South Med J,1990,83(11):1262-1265.
3Havdart GE,Fackler CJ.Predictors of intracranial hemorrhage during neonatal extracorporeal membrane oxygenation[J].J Pediatr,1999 134(2):156-159.
4Colman RW,Clowes AW.George JN.Overview of thrombosis[A].In:Colman RW,Marder VJ,Clowes AW,et al.eds.Hemostasis and thrombosis[M].5th ed.Philadelphia:Lippinincott Williams & Wilkins,2006.3-16.
5Uniyal S,Brash JL.Patterns of adsorption of proteins from human plasma onto foreign surfaces[J].Thromb Haemost,1982,47(3):285-290.
6Ziats NP,Pankowsky DA,Tierney BP,et al.Adsorption of Hageman factor (factor XII) and other plasma proteins to biomedical polymers[J].J Lab Clin Med,1990,116(5):687-696.
7Horbett TA.Principles underlying the role of adsorbed plasma proteins in blood interactions with foreign materials[J].Cardiovasc Pathol,1993,2(3S):137S-148S.
8Bowen FW,Edmunds Jr HL.Coagulation,anticoagulation and the interaction of blood and artificial surfaces[A].In:Zwischenberger JB,Steinhorn RH,Bartlett RH,editors.ECMO:extracorporeal cardiopulmonary support in critical care[M].2nd ed.Ann Arbor,Mich' ELSO,2000.67-96.
9Aird WC.Vascular bed-specific hemostasis:role of endothelium in sepsis pathogenesis[J].Crit Care Med,2001,29(7 Suppl):S28-34.
10Levi M,ten Cate H,van der Poll T.Endothelium:interface between coagulation and inflammation[J].Crit Care Med,2002,30(5 Suppl):S220-224.
2Edmunds LH Jr.Hastings lecture.Breaking the blood-biomaterial barrier[J].ASAIO J,1995,41(4):824-830.
3Baksaas ST,Videm V,Fosse E,et al.In vitro evaluation of new surface coatings for extracorporeal circulation[J].Perfusion,1999,14(1):11-19.
4Hioki I,Nishikawa M,Onoda K,et al.A heparin-coated circuit maintains platelet aggregability in response to shear stress in an in vitro model of cardiopulmonary bypass[J].Thromb Haemost,1998,80(3):437-442.
5Videm V,Nilsson L,Venge P,et al.Reduced granulocyte activation with a heparin-coated device in an in vitro model of cardiopulmonary bypass[J].Artif Organs,1991,15(2):90-95.
6Zwaal RF,Comfurius P,van Deenen LL.Membrane asymmetry and blood coagulation[J].Nature,1977,268(5618):358-360.
7Stammers AH,Christensen KA,Lynch J,et al.Quantitative evaluation of heparin-coated versus nonheparin-coated bypass circuits during cardiopulmonary bypass[J].J Extra Corpor Technol,1999,31(3):135-141.
8Mangoush O,Purkayastha S,Haj-Yahia S,et al.Heparin-bonded circuits versus nonheparin-bonded circuits:an evalutation of their effect on clinical coutcomes[J].Eur J Cardiothorac Surg,2007,31(6):1058-1069.
9Ovrum E,Tangen G,Oystese R,et al.Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations[J].J Thorac Cardiovasc Surg,2001,121(2):324-330.
10Ovrum E,Mollnes TE,Fosse E,et al.Complement and granulocyte activation in two different types of heparinized extracorporeal circuits[J].J Thorac Cardiovasc Surg,1995,110(6):1623-1632.
